Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.

This abstract provided no research findings as it contains only website navigation and service information.

This review highlights the possible impact of side effects from endocrine therapy on quality of life, emphasizing that these can lead to poor adherence and early treatment discontinuation in patients with hormone receptor positive early breast cancer, potentially worsening survival outcomes.

This review suggests that treating endocrine therapy-induced hair loss in breast cancer patients with topical 5-alpha reductase inhibitors and supplements like Vitamin C and omega-3 fatty acids may be effective, but further studies are needed.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

This document provides protocols for gender-affirming hormone therapy in India, highlighting the need for research on outcomes and adverse events in adults receiving such therapy; it reports no new results.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.

This review found that hormonal therapies, including FDA-approved combined oral contraceptive pills and spironolactone, are effective and well-tolerated treatments for acne vulgaris in adolescents with or without endocrine disorders, providing alternative options to antibiotics.

This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

This paper reviews the treatment options for hirsutism and emphasizes the importance of diagnosing its underlying cause and considering patient perception and specific phenotypes, reporting no new clinical results.

This review discusses guidelines for androgen use in women and concludes that more research is needed before recommending testosterone due to insufficient evidence on safety and efficacy.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

This study found that three months of metformin therapy improved acne, hirsutism, and menstrual irregularities in women with PCOS, along with hormonal and ultrasonographic changes.

This review identifies sebaceous gland disorders as key indicators of hormonal imbalances, detailing how various hormones affect sebaceous function, and emphasizes a multidisciplinary approach to improve diagnosis and management by integrating endocrine, metabolic, and dermatologic insights.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.

This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.

This review discusses the diagnosis, management, and hormone treatment of transsexual individuals, and examines the risks and effects of cross-sex hormone therapy without presenting new clinical results.

This review discusses the role of hormonal dysregulation and metabolic syndrome in hidradenitis suppurativa and reports no new clinical results.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This paper discusses hormonal therapy options for women with severe acne, focusing on treatment for cases that do not respond to conventional methods, but it reports no new clinical findings.

This review discusses the role of extracellular vesicles from specific skin cells in wound healing, emphasizing their potential in regenerative medicine and reporting no new experimental results.

This study observed that testosterone therapy in transgender men enhances both physical and mental health, is safe in the short and middle term with proper follow-up, and highlights the need for endocrinologists to provide gender-affirming care despite its limited presence in medical education.